lansoprazole has been researched along with Inflammation in 10 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lansoprazole inhibits lipid peroxidation and reduces development of intestinal mucosal inflammation induced by I/R in rats, suggesting that lansoprazole may have a therapeutic potential for I/R injury." | 7.72 | Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. ( Ichikawa, H; Isozaki, Y; Katada, K; Naito, Y; Okanoue, T; Takagi, T; Tomatsuri, N; Uchiyama, K; Yoshida, N; Yoshikawa, T, 2004) |
| " Laryngopharyngeal reflux patients underwent three-month lansoprazole treatment." | 3.83 | New inflammatory parameters in laryngopharyngeal reflux. ( Akmansu, ŞH; Arslan, H; Çandar, T; Kocatürk, S; Kuran, S, 2016) |
| "To explore whether proton pump inhibitors (PPIs) possess anti-inflammatory effects on microglia, we investigated the effect of lansoprazole (LPZ) and omeprazole (OPZ) on the toxic action towards SH-SY5Y neuroblastoma cells of supernatants from human microglia and THP-1 cells stimulated by lipopolysaccharide combined with interferon-gamma." | 3.75 | Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. ( Hashioka, S; Klegeris, A; McGeer, PL, 2009) |
| "Lansoprazole inhibits lipid peroxidation and reduces development of intestinal mucosal inflammation induced by I/R in rats, suggesting that lansoprazole may have a therapeutic potential for I/R injury." | 3.72 | Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. ( Ichikawa, H; Isozaki, Y; Katada, K; Naito, Y; Okanoue, T; Takagi, T; Tomatsuri, N; Uchiyama, K; Yoshida, N; Yoshikawa, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Hassanein, EHM | 1 |
| Kamel, EO | 1 |
| Gad-Elrab, WM | 1 |
| Ahmed, MA | 1 |
| Mohammedsaleh, ZM | 1 |
| Ali, FEM | 1 |
| Arslan, H | 1 |
| Çandar, T | 1 |
| Kuran, S | 1 |
| Akmansu, ŞH | 1 |
| Kocatürk, S | 1 |
| Hashioka, S | 1 |
| Klegeris, A | 1 |
| McGeer, PL | 1 |
| Nakagawa, S | 1 |
| Arai, Y | 1 |
| Kishida, T | 1 |
| Hiraoka, N | 1 |
| Tsuchida, S | 1 |
| Inoue, H | 1 |
| Sakai, R | 1 |
| Mazda, O | 1 |
| Kubo, T | 1 |
| Chuang, CH | 1 |
| Sheu, BS | 1 |
| Huang, AH | 1 |
| Yang, HB | 1 |
| Wu, JJ | 1 |
| Becker, TL | 1 |
| Maróstica, M | 1 |
| Ribeiro, ML | 1 |
| de Mendonça, S | 1 |
| Gambero, A | 1 |
| Pedrazzoli, J | 1 |
| Ichikawa, H | 1 |
| Yoshida, N | 1 |
| Takagi, T | 1 |
| Tomatsuri, N | 1 |
| Katada, K | 1 |
| Isozaki, Y | 1 |
| Uchiyama, K | 1 |
| Naito, Y | 1 |
| Okanoue, T | 1 |
| Yoshikawa, T | 1 |
| Bender, E | 1 |
| Schmidt, SP | 1 |
| Hendriks, HJ | 1 |
| van Kreel, B | 1 |
| Forget, PP | 1 |
1 trial available for lansoprazole and Inflammation
| Article | Year |
|---|---|
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; D | 2002 |
9 other studies available for lansoprazole and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Lansoprazole attenuates cyclophosphamide-induced cardiopulmonary injury by modulating redox-sensitive pathways and inflammation.
Topics: Animals; Cyclophosphamide; Cytoglobin; Inflammation; Lansoprazole; NF-E2-Related Factor 2; NF-kappa | 2023 |
New inflammatory parameters in laryngopharyngeal reflux.
Topics: Adult; Biomarkers; Case-Control Studies; Humans; Inflammation; Lansoprazole; Laryngopharyngeal Reflu | 2016 |
Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cell Survival; Cells, Cultured; Dose-Response Relationship, | 2009 |
Lansoprazole inhibits nitric oxide and prostaglandin E(2) production in murine macrophage RAW 264.7 cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Cell Line; Dinoprostone; | 2012 |
Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzi | 2004 |
Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Gastrointestinal Agents; Inflammation; Intestinal | 2004 |
Extraintestinal heterotopic gastric tissue simulating acute appendicitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acute Disease; Aged; Appendicitis; Choristo | 2008 |
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child | 2001 |